Last Updated: November 16, 2026

Details for Patent: 11,504,365

« Back to Dashboard


Which drugs does patent 11,504,365 protect, and when does it expire?

Patent 11,504,365 protects FOTIVDA and is included in one NDA.

This patent has nine patent family members in nine countries.

Summary for Patent: 11,504,365
Title:Use of tivozanib to treat subjects with refractory cancer
Abstract:Disclosed is a method of treating cancer, e.g., refractory cancer, with tivozanib. The methods disclosed include, for example, administering tivozanib as a second or third-line therapy to subjects suffering from refractory advanced renal cell carcinoma where traditional therapies as well as more recent targeted and immune-oncology therapies have not adequately treated the subject.
Inventor(s):Michael P. Bailey, Michael N. Needle
Assignee: Aveo Pharmaceuticals Inc
Application Number:US17/720,619
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 11,504,365

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aveo Pharms FOTIVDA tivozanib hydrochloride CAPSULE;ORAL 212904-001 Mar 10, 2021 RX Yes No 11,504,365 ⤷  Start Trial TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS ⤷  Start Trial
Aveo Pharms FOTIVDA tivozanib hydrochloride CAPSULE;ORAL 212904-002 Mar 10, 2021 RX Yes Yes 11,504,365 ⤷  Start Trial TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,504,365

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2019375972 ⤷  Start Trial
Brazil 112021008606 ⤷  Start Trial
Canada 3118690 ⤷  Start Trial
Chile 2021001172 ⤷  Start Trial
Eurasian Patent Organization 202191273 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.